Personalis (PSNL) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 21.74%. A quarter ago, it was expected that this provider of contract research and genomic information would post a loss of $0.25 per share when it actually produced a loss of $0.23, delivering a surprise of 8%. Over the last ...

Personalis (PSNL) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Company Participants Caroline Corner - Investor RelationsChristopher Hall - CEO and PresidentAaron Tachibana - CFO & COORichard Chen - Executive VP of R&D and Chief Medical OfficerVidyun Bais - Equity Research - Vice PresidentYuko Oku - Equity Research Associate Conference Call Participants Thomas Flaten - Senior Research AnalystWilliam Bonello - Senior Research AnalystJoseph Stringer - Senior AnalystDaniel Brennan - Senior Equity Research Ana ...

Personalis (PSNL) Q1 2025 Earnings Call May 06, 2025 05:00 PM ET Speaker0 Greetings. Welcome to the Personalis First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. Please note this conference is being recorded. I would now like to turn the call over to Caroline Corner. Please go ahead. Speaker1 Thank you, operator. Welcome to Personalis' first quarter twenty twenty five earnings ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38943 Personalis, Inc. (Exact Name of registrant as specified in its charter) (State or other jurisdiction of incorporatio ...

FREMONT, Calif. – May 6, 2025 – Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights. Recent Business Highlights "This year is off to a great start, with strong first quarter testing growth, and we remain confident that our "Win-in-MRD" strategy is working," said Chris Hall, Chief Executive Officer and President. "We crossed the milestone of 2,000 tes ...

The Hanover Insurance Group (THG) is expected to register an improvement in its top and bottom lines when it reports first-quarter 2025 results on April 30, after the closing bell.The Zacks Consensus Estimate for THG’s first-quarter revenues is pegged at $1.7 billion, indicating a 6.5% increase from the year-ago reported figure. The consensus estimate for the bottom line is pegged at $3.58 per share. The estimate suggests a year-over-year increase of 144.4%. The Zacks Consensus Estimate for THG’s first-quar ...

Personalis, Inc. (NASDAQ:PSNL) Q4 2024 Earnings Conference Call February 27, 2025 5:00 PM ET Company Participants Caroline Corner - Investor Relations Christopher Hall - Chief Executive Officer and President Aaron Tachibana - Chief Financial and Chief Operating Officer Richard Chen - Executive Vice President, R&D, and Chief Medical Officer Conference Call Participants Thomas Flaten - Lake Street Swayampakula Ramakanth - H.C. Wainwright William Ruby - TD Cowen Operator Ladies and gentlemen, greetings and wel ...

Company Performance - Personalis reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.25, and an improvement from a loss of $0.46 per share a year ago, representing an earnings surprise of 8% [1] - The company posted revenues of $16.8 million for the quarter ended December 2024, slightly surpassing the Zacks Consensus Estimate by 0.06%, but down from $19.68 million in the same quarter last year [2] - Over the last four quarters, Personalis has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Outlook - Personalis shares have declined approximately 22.5% since the beginning of the year, contrasting with the S&P 500's gain of 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.26 on revenues of $15.22 million, and for the current fiscal year, it is -$0.99 on revenues of $85.13 million [7] - The estimate revisions trend for Personalis is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Medical - Generic Drugs industry, to which Personalis belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Personalis's stock performance [5]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission File Number 001-38943 Personalis, Inc. (Exact name of Registrant as specified in its Charter) Delaware 27-5411038 (State or other jurisdiction ...

Wall Street expects a year-over-year increase in earnings on lower revenues when Personalis (PSNL) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 27. ...